Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Genomics (NASDAQ:TXG – Free Report) had its price objective decreased by UBS Group from $20.00 to $14.00 in a research report ...

Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating ...

Genomics (NASDAQ:TXG – Free Report) had its price objective lowered by Canaccord Genuity Group from $20.00 to $18.00 in a ...

Genomics (NASDAQ:TXG – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $14.00 to $12.00 in a research note issued to investors on Thursday morning,Benzinga reports. The ...

Three of IWS's underlying holdings with notable upside to their analyst target prices are Ionis Pharmaceuticals Inc (Symbol: IONS), 10x Genomics Inc (Symbol: TXG), and Enovis Corp (Symbol ...

Genomics (NASDAQ:TXG – Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect 10x Genomics to post earnings of ($0.29) per ...